Imiquimod-induced vitiligo after treatment of nodular basal cell carcinoma

Journal of Cutaneous Pathology

Volumn 36, Issue 8, 2009, Pages 878-881

  Gowda, Smitha ^a   Tillman, Donald K ^b   Fitzpatrick, James E ^c   Gaspari, Anthony A ^a   Goldenberg, Gary ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b Great Plains Dermatology   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD; MELAN A; MELANIN; PROTEIN S 100;

AGED; ARTICLE; BASAL CELL CARCINOMA; CASE REPORT; CREAM; DRUG WITHDRAWAL; HISTOLOGY; HUMAN; INFLAMMATION; MALE; MELANOCYTE; NODULAR BASAL CELL CARCINOMA; RECURRENT CANCER; SHOULDER; SKIN BIOPSY; TREATMENT DURATION; TREATMENT WITHDRAWAL; VITILIGO;

AGED, 80 AND OVER; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; HUMANS; MALE; MELANOCYTES; SKIN; SKIN NEOPLASMS; TIME FACTORS; VITILIGO;

EID: 67650685606     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2008.01134.x     Document Type: Article

References (25)

1. Chang YC, Madkan V, Cook-Norris R, et al. Current and potential uses of imiquimod. South Med J 2005 98 : 913.
2. Gaspari AA. Mechanism of action and other potential roles of an immune response modifier. Cutis 2007 79 : 36.
3. Brown T, Zirvi M, Cotsarelis G, et al. Vitiligo-like hypopigmentation associated with imiquimod treatment of genital warts. J Am Acad Dermatol 2005 52 : 715.
4. Stefanaki C, Nicolaidou E, Hadjivassiliou M, et al. Imiquimod-induced vitiligo in a patient with genital warts. J Eur Acad Dermatol Venereol 2006 20 : 755.
5. Al-Dujaili Z, Hsu S. Imiquimod-induced vitiligo. Dermatol Online J 2007 13 : 10.
6. Senel E, Seckin D. Imiquimod-induced vitiligo-like depigmentation. Indian J Dermatol Venereol Leprol 2007 73 : 423. (Pubitemid 350166084)
7. Mendonca CO, Yates VM. Permanent facial hypopigmentation following treatment with imiquimod cream. Clin Exp Dermatol 2006 31 : 721.
8. Mashiah J, Brenner S. Possible mechanisms in the induction of vitiligo-like hypopigmentation by topical imiquimod. Clin Exp Dermatol 2008 33 : 74.
9. Neville JA, Williford PM, Jorizzo JL. Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage. J Drugs Dermatol 2007 6 : 910.
10. Gupta AK, Browne M, Bluhm R. Imiquimod: a review. J Cutan Med Surg 2002 6 : 554.
11. Burns CA, Brown MD. Imiquimod for the treatment of skin cancer. Dermatol Clin 2005 23 : 151, vii.
12. Woodmansee C, Pillow J, Skinner RB Jr. The role of topical immune response modifiers in skin cancer. Drugs 2006 66 : 1657.
13. Goldenberg G, Krowchuk DP, Jorizzo JL. Successful treatment of a therapy-resistant pyogenic granuloma with topical imiquimod 5% cream. J Dermatolog Treat 2006 17 : 121.
14. Taylor CL, Maslen M, Kapembwa M. A case of severe eczema following use of imiquimod 5% cream. Sex Transm Infect 2006 82 : 227.
15. Mashiah J, Brenner S. Possible mechanisms in the induction of pemphigus foliaceus by topical imiquimod treatment. Arch Dermatol 2005 141 : 908.
16. Urosevic M, Maier T, Benninghoff B, et al. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol 2003 139 : 1325.
17. Berman B, Sullivan T, De Araujo T, et al. Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle. Br J Dermatol 2003 149 (Suppl. 66 59.
18. Ongenae K, Van Geel N, Naeyaert JM. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res 2003 16 : 90.
19. Moretti S, Spallanzani A, Amato L, et al. New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res 2002 15 : 87.
20. Le Poole IC, Wankowicz-Kalinska A, van den Wijngaard RM, et al. Autoimmune aspects of depigmentation in vitiligo. J Investig Dermatol Symp Proc 2004 9 : 68.
21. Wañkowicz-Kaliñska A, van den Wijngaard RM, Tigges BJ, et al. Immunopolarization of CD4+ and CD8+ T cells to Type-1-like is associated with melanocyte loss in human vitiligo. Lab Invest 2003 83 : 683.
22. Spencer JM. Pilot study of imiquimod 5% cream as adjunctive therapy to curettage and electrodesiccation for nodular basal cell carcinoma. Dermatol Surg 2006 32 : 63.
23. Wu JK, Oh C, Strutton G, et al. An open-label, pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma. Australas J Dermatol 2006 47 : 46.
24. Tillman DK Jr., Carroll MT. A 36-month clinical experience of the effectiveness of curettage and imiquimod 5% cream in the treatment of basal cell carcinoma. J Drugs Dermatol 2008 7 : s7.
25. Sheridan AT, Dawber RP. Curettage, electrosurgery and skin cancer. Australas J Dermatol 2000 41 : 19.